Effiong Andem
Faculty of Medicine, Memorial University, St John's, NL, Canada.
JMIRx Med. 2023 Mar 14;4:e43880. doi: 10.2196/43880.
The postacute sequelae of COVID-19 (PASC) is a syndrome characterized by persistent COVID-19 symptoms or the onset of new symptoms following recovery from the initial or acute phase of the illness. Such symptoms often occur 4 or more weeks after being diagnosed with COVID-19. Although a lot of work has gone into understanding the long-term mental health effects of PASC, many questions related to the etiology and risk of this condition remain.
This protocol is for a systematic review assessing the association between PASC and adverse psychiatric outcomes and whether people with PASC are at greater risk of developing an adverse psychiatric outcome than those without PASC.
Various medical literature databases (eg, PubMed and EMBASE) will be searched for eligible articles, using predefined search criteria. Gray literature will also be explored. Epidemiological observational studies and secondary analyses of randomized controlled trials that report a quantitative relationship between PASC and at least one adverse psychiatric outcome will be included. The Population, Exposure of interest, Comparator, and Outcome framework will be used as a standardized framework for the inclusion criteria. The Joanna Briggs Institute critical appraisal tools will be used to assess methodological quality and critically appraise the risk of bias in included studies. A random-effects meta-analysis will be conducted if possible. A formal narrative synthesis will be performed if a meta-analysis is impossible due to substantial heterogeneity across studies. The Grading of Recommendations Assessment, Development and Evaluation approach will be used to rate the cumulative certainty of the evidence for all outcomes. Ethical approval is not required. The study results will be published in a peer-reviewed journal.
This study documents and addresses etiology, risk factors, and long-term symptoms of COVID-19 among people with PASC. It focuses on a key priority area for new evidence syntheses on the clinical management of COVID-19 and pandemic-related conditions. It will include evidence on nonhospitalized and hospitalized patients with a history of PASC.
Substantial heterogeneity across studies may limit the ability to perform a meta-analysis. Findings will inform disease prevention, decision-making, health care policy, and clinical research (Reviewed by the Plan P #PeerRef Community).
PROSPERO CRD42022308737; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=308737.
2019冠状病毒病的急性后后遗症（PASC）是一种综合征，其特征为持续存在的2019冠状病毒病症状，或在疾病初始或急性期康复后出现新症状。此类症状通常在确诊感染2019冠状病毒病4周或更长时间后出现。尽管在了解PASC对长期心理健康的影响方面已开展了大量工作，但与该病症的病因和风险相关的许多问题仍然存在。
本方案旨在进行一项系统评价，评估PASC与不良精神科结局之间的关联，以及患有PASC的人发生不良精神科结局的风险是否高于未患PASC的人。
将使用预定义的检索标准，在各种医学文献数据库（如PubMed和EMBASE）中检索符合条件的文章。还将探索灰色文献。将纳入报告PASC与至少一种不良精神科结局之间定量关系的流行病学观察性研究和随机对照试验的二次分析。人群、感兴趣的暴露因素、对照和结局框架将用作纳入标准的标准化框架。将使用乔安娜·布里格斯研究所的批判性评价工具来评估方法学质量，并严格评价纳入研究中的偏倚风险。如有可能，将进行随机效应荟萃分析。如果由于各研究之间存在实质性异质性而无法进行荟萃分析，则将进行正式的叙述性综合分析。推荐分级评估、制定和评价方法将用于对所有结局证据的累积确定性进行评级。无需伦理批准。研究结果将发表在同行评审期刊上。
本研究记录并探讨了患有PASC的人群中2019冠状病毒病的病因、危险因素和长期症状。它关注的是2019冠状病毒病及大流行相关病症临床管理新证据综合的一个关键优先领域。它将纳入有PASC病史的非住院和住院患者的证据。
各研究之间存在的实质性异质性可能会限制进行荟萃分析的能力。研究结果将为疾病预防、决策、卫生保健政策和临床研究提供信息（由计划P#同行评审社区审核）。
PROSPERO CRD42022308737；https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=308737 。
